<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The efficacy of <z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) in patients with <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> (APL) has been well documented </plain></SENT>
<SENT sid="1" pm="."><plain>However, ATRA is not as effective against other types of <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We present a patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (FAB: M2) associated with a t(2;17;4)(p13;q21;p16) chromosomal defect in which the 17q21 breakpoint was not within the <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> receptor alpha locus which is typically rearranged in APL </plain></SENT>
<SENT sid="3" pm="."><plain>This patient was successfully treated with ATRA and granulocyte colony-stimulating factor and improvement of hematological parameters lasted for 19 months without the use of cytotoxic agents </plain></SENT>
</text></document>